Glück Conviction Score™ ⓘ
CRNX
Crinetics Pharmaceuticals, Inc.
Effektiv: Schwach
Mittel
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
44,7
43 neu, 117 erhöht, -606233K $ netto
Aktivist
13,6
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bärisch | 10 % | 37.46 | -8.0 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 41.65 | -17.2 % vs SMA200 | |
| SMA-Cross | Bärisch | 10 % | DEATH | vor 41 Tagen @ 39.77 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 35.12 | EMA50: 36.93 | |
| MACD-Histogramm | Bullisch | 10 % | 0.040 | Bullisch | |
| RSI(14) | Neutral | 10 % | 45.5 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 42.9 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 14.4 | +DI: 21.5 / −DI: 24.9 | |
| Z-Score(60) | Neutral | 5 % | -1.09 | In Range | |
| 52W-Position | Neutral | 5 % | 25.8 % | Hoch 56.43 / Tief 26.85 | |
| Bollinger(20,2σ) | Neutral | 5 % | 40.3 % | Upper 37.82 / Mid 35.01 / Lower 32.20 | |
| LinReg-Slope(60) | Neutral | 10 % | -0.0452 | R²=0.10 / annualisiert -30.7 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-08 | Knight Jeff E. | Officer, Chief Dev. & Operating Officer | Open Market Sale | -85.163 | 40,10 | -3.415.036,30 | -842,4% | |
| 2026-03-16 | Struthers Richard Scott | Director, Officer, President & CEO | Open Market Sale | -13.196 | 37,11 | -489.703,56 | -120,8% | |
| 2026-03-16 | Knight Jeff E. | Officer, Chief Operating Officer | Open Market Sale | -3.961 | 37,77 | -149.606,97 | -36,9% | |
| 2026-03-16 | Betz Stephen F. | Officer, Chief Scientific Officer | Open Market Sale | -6.371 | 37,11 | -236.427,81 | -58,3% | |
| 2026-03-16 | Betz Stephen F. | Officer, Chief Scientific Officer | Open Market Sale | -4.241 | 37,77 | -160.182,57 | -39,5% | |
| 2026-03-16 | Knight Jeff E. | Officer, Chief Operating Officer | Open Market Sale | -5.950 | 37,11 | -220.804,50 | -54,5% | |
| 2026-03-16 | Struthers Richard Scott | Director, Officer, President & CEO | Open Market Sale | -8.785 | 37,77 | -331.809,45 | -81,8% | |
| 2026-03-12 | Vivaldi Coelho Rogerio | Director | Open Market Sale | -4.477 | 36,08 | -161.530,16 | -39,8% | |
| 2026-03-12 | Vivaldi Coelho Rogerio | Director | Open Market Sale | -523 | 36,77 | -19.230,71 | -4,7% | |
| 2026-03-03 | Schilke Tobin | Officer, Chief Financial Officer | Open Market Sale | -6.713 | 39,67 | -266.304,71 | -65,7% | |
| 2026-03-03 | Okey Stephanie | Director | Open Market Sale | -3.000 | 39,67 | -119.010,00 | -29,4% | |
| 2026-01-05 | Kalofonos Isabel | Officer, Chief Commercial Officer | Open Market Sale | -2.500 | 55,00 | -137.500,00 | -33,9% | |
| 2025-12-01 | Pizzuti Dana | Officer, Chief Med and Dev Officer | Open Market Sale | -5.000 | 45,02 | -225.100,00 | -55,5% | |
| 2025-11-03 | Pizzuti Dana | Officer, Chief Med and Dev Officer | Open Market Sale | -4.900 | 42,65 | -208.985,00 | -51,6% | |
| 2025-11-03 | Pizzuti Dana | Officer, Chief Med and Dev Officer | Open Market Sale | -100 | 43,27 | -4.327,00 | -1,1% | |
| 2025-10-01 | Pizzuti Dana | Officer, Chief Med and Dev Officer | Open Market Sale | -5.000 | 41,81 | -209.050,00 | -51,6% | |
| 2025-09-26 | Struthers Richard Scott | Director, Officer, President & CEO | Open Market Sale | -4.000 | 45,00 | -180.000,00 | -44,4% | |
| 2025-09-26 | Fust Matthew K | Director | Open Market Sale | -16.000 | 44,75 | -716.000,00 | -176,6% | |
| 2025-09-02 | Pizzuti Dana | Officer, Chief Med and Dev Officer | Open Market Sale | -5.000 | 32,10 | -160.500,00 | -39,6% | |
| 2025-08-22 | Pizzuti Dana | Officer, Chief Med and Dev Officer | Open Market Sale | -30.000 | 30,43 | -912.900,00 | -225,2% | |
| 2025-08-20 | Pizzuti Dana | Officer, Chief Med and Dev Officer | Open Market Sale | -6.492 | 29,18 | -189.436,56 | -46,7% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| FMR LLC | 15.759.799 | 14.293.775 | 1.466.024 | 572.395.895 | Aufgestockt | +10,3% | |
| VANGUARD GROUP INC | 9.135.504 | 0 | 9.135.504 | 425.257.712 | Neu | +100,0% | |
| BlackRock, Inc. | 8.478.815 | 7.988.548 | 490.267 | 307.950.573 | Aufgestockt | +6,1% | |
| FARALLON CAPITAL MANAGEMENT LLC | 8.338.098 | 0 | 8.338.098 | 302.839.719 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 8.157.204 | 8.037.889 | 119.315 | 296.269.650 | Aufgestockt | +1,5% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 6.395.922 | 6.387.740 | 8.182 | 232.299.887 | Aufgestockt | +0,1% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.673.935 | 0 | 4.673.935 | 169.757.319 | Neu | +100,0% | |
| JANUS HENDERSON GROUP PLC | 4.520.251 | 4.440.691 | 79.560 | 164.227.195 | Aufgestockt | +1,8% | |
| EcoR1 Capital, LLC | 4.288.120 | 4.288.120 | 0 | 155.744.518 | Unverändert | 0,0% | |
| Bellevue Group AG | 3.280.000 | 4.040 | 3.275.960 | 119.129.600 | Aufgestockt | +81088,1% | |
| Point72 Asset Management, L.P. | 2.337.034 | 0 | 2.337.034 | 108.788.933 | Neu | +100,0% | |
| Paradigm Biocapital Advisors LP | 2.210.774 | 0 | 2.210.774 | 102.911.530 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.480.763 | 2.242.631 | 238.132 | 90.119.429 | Aufgestockt | +10,6% | |
| STATE STREET CORP | 2.403.046 | 2.161.378 | 241.668 | 87.278.631 | Aufgestockt | +11,2% | |
| BAKER BROS. ADVISORS LP | 2.351.465 | 1.648.869 | 702.596 | 85.405.209 | Aufgestockt | +42,6% | |
| Siren, L.L.C. | 1.903.636 | 1.507.636 | 396.000 | 69.140.060 | Aufgestockt | +26,3% | |
| Pictet Asset Management Holding SA | 1.884.281 | 1.560.300 | 323.981 | 68.204.218 | Aufgestockt | +20,8% | |
| BNP Paribas Asset Management Holding S.A. | 1.716.445 | 1.327.382 | 389.063 | 62.341.282 | Aufgestockt | +29,3% | |
| Novo Holdings A/S | 1.550.000 | 1.625.000 | -75.000 | 56.296.000 | Reduziert | -4,6% | |
| JPMORGAN CHASE & CO | 1.154.710 | 0 | 1.154.710 | 53.751.750 | Neu | +100,0% | |
| RTW INVESTMENTS, LP | 1.451.326 | 1.351.326 | 100.000 | 52.712.160 | Aufgestockt | +7,4% | |
| ADAR1 Capital Management, LLC | 1.139.331 | 309.368 | 829.963 | 41.380.502 | Aufgestockt | +268,3% | |
| First Light Asset Management, LLC | 1.089.670 | 1.194.263 | -104.593 | 39.576.814 | Reduziert | -8,8% | |
| AMERICAN CENTURY COMPANIES INC | 1.052.858 | 1.068.878 | -16.020 | 38.239.852 | Reduziert | -1,5% | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1.043.879 | 0 | 1.043.879 | 37.913.685 | Neu | +100,0% | |
| ORBIMED ADVISORS LLC | 999.000 | 999.000 | 0 | 36.283.680 | Unverändert | 0,0% | |
| MORGAN STANLEY | 919.686 | 768.826 | 150.860 | 33.403.019 | Aufgestockt | +19,6% | |
| Hood River Capital Management LLC | 907.412 | 897.403 | 10.009 | 32.957.204 | Aufgestockt | +1,1% | |
| JENNISON ASSOCIATES LLC | 904.672 | 1.281.601 | -376.929 | 32.857.688 | Reduziert | -29,4% | |
| DIMENSIONAL FUND ADVISORS LP | 852.258 | 548.977 | 303.281 | 30.935.100 | Aufgestockt | +55,2% | |
| NORTHERN TRUST CORP | 841.301 | 769.823 | 71.478 | 30.556.054 | Aufgestockt | +9,3% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 833.418 | 781.981 | 51.437 | 30.269.742 | Aufgestockt | +6,6% | |
| Candriam S.C.A. | 830.961 | 830.961 | 0 | 30.180.504 | Unverändert | 0,0% | |
| Aberdeen Group plc | 820.395 | 674.533 | 145.862 | 29.796.746 | Aufgestockt | +21,6% | |
| AMERIPRISE FINANCIAL INC | 798.334 | 601.190 | 197.144 | 28.995.559 | Aufgestockt | +32,8% | |
| Fisher Asset Management, LLC | 762.702 | 758.659 | 4.043 | 27.701.335 | Aufgestockt | +0,5% | |
| BANK OF AMERICA CORP /DE/ | 716.125 | 801.314 | -85.189 | 26.009.660 | Reduziert | -10,6% | |
| MARSHALL WACE, LLP | 684.108 | 0 | 684.108 | 24.846.804 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 628.155 | 567.127 | 61.028 | 22.814.589 | Aufgestockt | +10,8% | |
| Fiera Capital Corp | 589.654 | 578.455 | 11.199 | 21.416.233 | Aufgestockt | +1,9% | |
| UBS Group AG | 571.899 | 908.192 | -336.293 | 20.771.372 | Reduziert | -37,0% | |
| Nuveen, LLC | 551.464 | 522.466 | 28.998 | 20.029.173 | Aufgestockt | +5,6% | |
| Ikarian Capital, LLC | 368.500 | 0 | 368.500 | 17.153.675 | Neu | +100,0% | |
| Universal- Beteiligungs- und Servicegesellschaft mbH | 425.616 | 408.312 | 17.304 | 15.458.373 | Aufgestockt | +4,2% | |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 382.363 | 187.433 | 194.930 | 13.103.580 | Aufgestockt | +104,0% | |
| Prosight Management, LP | 350.000 | 262.904 | 87.096 | 12.712.000 | Aufgestockt | +33,1% | |
| Impax Asset Management Group plc | 350.000 | 275.000 | 75.000 | 12.712.000 | Aufgestockt | +27,3% | |
| CITADEL ADVISORS LLC | 346.134 | 284.420 | 61.714 | 12.571.587 | Aufgestockt | +21,7% | |
| BRAUN STACEY ASSOCIATES INC | 324.808 | 0 | 324.808 | 11.797.027 | Neu | +100,0% | |
| VOYA INVESTMENT MANAGEMENT LLC | 306.039 | 302.001 | 4.038 | 11.115.337 | Aufgestockt | +1,3% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| FMR LLC | 15.759.799 | 14.293.775 | +10,3% | 572.395.895 | 14,61 |
| BlackRock, Inc. | 8.478.815 | 7.988.548 | +6,1% | 307.950.573 | 7,86 |
| FARALLON CAPITAL MANAGEMENT LLC | 8.338.098 | 0 | +100,0% | 302.839.719 | 7,73 |
| WELLINGTON MANAGEMENT GROUP LLP | 8.157.204 | 8.037.889 | +1,5% | 296.269.650 | 7,56 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 6.395.922 | 6.387.740 | +0,1% | 232.299.887 | 5,93 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.673.935 | 0 | +100,0% | 169.757.319 | 4,33 |
| JANUS HENDERSON GROUP PLC | 4.520.251 | 4.440.691 | +1,8% | 164.227.195 | 4,19 |
| EcoR1 Capital, LLC | 4.288.120 | 4.288.120 | 0,0% | 155.744.518 | 3,98 |
| Bellevue Group AG | 3.280.000 | 4.040 | +81088,1% | 119.129.600 | 3,04 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.480.763 | 2.242.631 | +10,6% | 90.119.429 | 2,30 |
| STATE STREET CORP | 2.403.046 | 2.161.378 | +11,2% | 87.278.631 | 2,23 |
| BAKER BROS. ADVISORS LP | 2.351.465 | 1.648.869 | +42,6% | 85.405.209 | 2,18 |
| Siren, L.L.C. | 1.903.636 | 1.507.636 | +26,3% | 69.140.060 | 1,76 |
| Pictet Asset Management Holding SA | 1.884.281 | 1.560.300 | +20,8% | 68.204.218 | 1,74 |
| BNP Paribas Asset Management Holding S.A. | 1.716.445 | 1.327.382 | +29,3% | 62.341.282 | 1,59 |
| Novo Holdings A/S | 1.550.000 | 1.625.000 | -4,6% | 56.296.000 | 1,44 |
| RTW INVESTMENTS, LP | 1.451.326 | 1.351.326 | +7,4% | 52.712.160 | 1,35 |
| JPMORGAN CHASE & CO | 1.324.668 | 1.154.710 | +14,7% | 45.396.372 | 1,16 |
| ADAR1 Capital Management, LLC | 1.139.331 | 309.368 | +268,3% | 41.380.502 | 1,06 |
| First Light Asset Management, LLC | 1.089.670 | 1.194.263 | -8,8% | 39.576.814 | 1,01 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 242 | 132,0 | 4.461 |
| 31.12.2025 | ✓ | 244 | 114,9 | 4.962 |
| 30.09.2025 | ✓ | 227 | 117,3 | 4.585 |
| 30.06.2025 | ✓ | 220 | 105,3 | 2.774 |
| 31.03.2025 | ✓ | 221 | 107,1 | 3.314 |
| 31.12.2024 | ✓ | 242 | 101,0 | 4.673 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| Impax Asset Management Group plc | 275.000 | 12.801.250 |
| GordonMD Global Investments LP | 224.135 | 10.433.484 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 144.239 | 6.714.325 |
| SECTOR GAMMA AS | 115.000 | 5.353.250 |
| CASTLEARK MANAGEMENT LLC | 62.790 | 2.922.875 |
| Man Group plc | 62.560 | 2.912.168 |
| Walleye Trading LLC | 50.600 | 2.355.430 |
| Vestmark Advisory Solutions, Inc. | 46.552 | 2.166.996 |
| RAYMOND JAMES FINANCIAL INC | 33.354 | 1.552.624 |
| Progeny 3, Inc. | 24.000 | 1.117.200 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 1.648.869 | 1.368.869 | +488.9 % | 76.754.852 |
| GW&K Investment Management, LLC | 1.476.325 | 625.779 | +73.6 % | 68.723 |
| JANUS HENDERSON GROUP PLC | 4.440.691 | 581.900 | +15.1 % | 206.603.847 |
| UBS Group AG | 908.192 | 500.470 | +122.7 % | 42.276.338 |
| BNP Paribas Asset Management Holding S.A. | 1.327.382 | 493.351 | +59.2 % | 61.789 |
| RTW INVESTMENTS, LP | 1.351.326 | 478.939 | +54.9 % | 62.904.225 |
| BlackRock, Inc. | 7.988.548 | 401.951 | +5.3 % | 371.866.926 |
| Aberdeen Group plc | 674.533 | 334.584 | +98.4 % | 31.399.511 |
| Point72 Asset Management, L.P. | 2.337.034 | 333.701 | +16.7 % | 108.788.933 |
| VOYA INVESTMENT MANAGEMENT LLC | 302.001 | 267.307 | +770.5 % | 14.058.147 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| JENNISON ASSOCIATES LLC | 1.281.601 | -763.133 | -37.3 % | 59.658.525 |
| CITADEL ADVISORS LLC | 284.420 | -747.087 | -72.4 % | 13.239.751 |
| WELLINGTON MANAGEMENT GROUP LLP | 8.037.889 | -344.102 | -4.1 % | 374.163.733 |
| Paradigm Biocapital Advisors LP | 2.210.774 | -340.000 | -13.3 % | 102.911.530 |
| ORBIMED ADVISORS LLC | 999.000 | -200.000 | -16.7 % | 46.503.450 |
| Siren, L.L.C. | 1.507.636 | -180.975 | -10.7 % | 70.180.456 |
| JANE STREET GROUP, LLC | 17.600 | -146.282 | -89.3 % | 819.280 |
| GOLDMAN SACHS GROUP INC | 567.127 | -146.003 | -20.5 % | 26.399.762 |
| ROYAL BANK OF CANADA | 47.295 | -123.200 | -72.3 % | 2.202.000 |
| Caption Management, LLC | 75.100 | -113.100 | -60.1 % | 3.495.905 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 15.05.2026 | DRIEHAUS CAPITAL MANAGEMENT LLC | Passiv (13G/A) | 6,11 % | 6.395.922 | -1,43 pp | |
| 15.05.2026 | Wellington Group Holdings LLP | Passiv (13G/A) | 7,80 % | 8.157.204 | -1,10 pp | |
| 15.05.2026 | Wellington Management Group LLP | Passiv (13G/A) | 7,80 % | 8.157.204 | -1,10 pp | |
| 15.05.2026 | Wellington Investment Advisors Holdings LLP | Passiv (13G/A) | 7,80 % | 8.157.204 | -1,10 pp | |
| 15.05.2026 | Wellington Management Company LLP | Passiv (13G/A) | 7,40 % | 8.157.204 | -1,00 pp | |
| 15.05.2026 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 5,10 % | 5.355.011 | Neu | |
| 29.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,19 % | 5.440.646 | Neu | |
| 26.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -10,00 pp | |
| 05.02.2026 | Farallon Healthcare Partners Master, L.P. | Passiv (13G/A) | 4,90 % | 4.682.318 | +1,40 pp | |
| 05.02.2026 | Giauque, Nicolas | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Four Crossings Institutional Partners V, L.P. | Passiv (13G/A) | 0,10 % | 135.338 | 0,00 pp | |
| 05.02.2026 | Wehrly, Mark C. | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Farallon Healthcare Partners (GP), L.L.C. | Passiv (13G/A) | 4,90 % | 4.682.318 | +1,40 pp | |
| 05.02.2026 | Farallon Capital (AM) Investors, L.P. | Passiv (13G/A) | 0,10 % | 72.967 | 0,00 pp | |
| 05.02.2026 | Warren, John R. | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Spokes, Andrew J. M. | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Farallon F5 (GP), L.L.C. | Passiv (13G/A) | 0,20 % | 197.760 | 0,00 pp | |
| 05.02.2026 | Gehani, Varun N. | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Short Daniel S. | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Farallon Partners, L.L.C. | Passiv (13G/A) | 8,20 % | 7.826.338 | +2,40 pp | |
| 05.02.2026 | Roberts, Jr., Thomas G. | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Farallon Capital Institutional Partners III, L.P. | Passiv (13G/A) | 0,10 % | 103.335 | 0,00 pp | |
| 05.02.2026 | Farallon Capital Partners, L.P. | Passiv (13G/A) | 0,60 % | 584.527 | +0,20 pp | |
| 05.02.2026 | Saito Edric C. | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Dapice Joshua J. | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Farallon Capital Institutional Partners II, L.P. | Passiv (13G/A) | 0,20 % | 168.850 | +0,10 pp | |
| 05.02.2026 | Linn, Michael G. | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Farallon Capital F5 Master I, L.P. | Passiv (13G/A) | 0,20 % | 197.760 | 0,00 pp | |
| 05.02.2026 | Fried, Richard B | Passiv (13G/A) | Ausstieg | 0 | -6,00 pp | |
| 05.02.2026 | Dreyfuss, Philip D. | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Farallon Capital Offshore Investors II, L.P. | Passiv (13G/A) | 1,40 % | 1.369.733 | +0,40 pp | |
| 05.02.2026 | Husen, Avner A. | Passiv (13G/A) | 8,50 % | 8.024.098 | Neu | |
| 05.02.2026 | Kim, David T. | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Farallon Capital Institutional Partners, L.P. | Passiv (13G/A) | 0,70 % | 709.270 | +0,20 pp | |
| 05.02.2026 | Dunn Hannah E. | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Luo Patrick (Cheng) | Passiv (13G/A) | 8,50 % | 8.024.098 | +2,50 pp | |
| 05.02.2026 | Farallon Institutional (GP) V, L.L.C. | Passiv (13G/A) | 0,10 % | 135.338 | 0,00 pp | |
| 05.02.2026 | Patel, Rajiv A. | Passiv (13G/A) | Ausstieg | 0 | -6,00 pp | |
| 05.02.2026 | Seybold, William | Passiv (13G/A) | Ausstieg | 0 | -6,00 pp | |
| 12.11.2025 | Wellington Investment Advisors Holdings LLP | Passiv (13G/A) | 8,90 % | 8.381.991 | +2,70 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 03.03.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 17.04.2025 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 19.03.2025 | Josh Gottheimer | – | House | Verkauf | $1,001 – $15,000 |
| 29.01.2025 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 25.09.2024 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Stammdaten
Crinetics Pharmaceuticals, Inc., ein klinisches Stadiumpharmaunternehmen, konzentriert sich auf die Entdeckung, Entwicklung und Kommerzialisierung von Therapeutika für seltene endokrine Erkrankungen und endokrinbezogene Tumoren. Der Leitproduktkandidat ist Paltusotine, ein orales, selektives nicht-peptidisches Somatostatinrezeptor-Typ-2-Agonist, das die Phase-III-Studie für die Behandlung von Akromegalie abgeschlossen hat und die Phase-II-Studie für die Behandlung des Karzinoid-Syndroms und nicht funktionaler neuroendokriner Tumoren (NETs) abgeschlossen hat. Das Unternehmen entwickelt außerdem CRN04777, einen oralen, selektiven nicht-peptidischen Somatostatintyp-5-Rezeptor-Agonisten, der sich in der Phase-I-Studie für die Behandlung des angeborenen Hyperinsulinismus befindet, sowie CRN04894, einen oralen adrenokortikotropen-Hormon-Antagonisten, der sich in der Phase-I-Studie für die Behandlung des Cushing-Syndroms und der angeborenen Nebennierenrindenhyperplasie befindet. Crinetics Pharmaceuticals, Inc. wurde 2008 gegründet und hat seinen Sitz in San Diego, Kalifornien.
Unternehmen & Branche
| Name | Crinetics Pharmaceuticals, Inc. |
|---|---|
| Ticker | CRNX |
| CIK | 0001658247 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 22663k107 |
|---|---|
| ISIN | US22663K1079 |
| Typ | Common Stock |
| Marktkapitalisierung | 3,20 Mrd. USD |
| Beta | 0,26 |
Bewertung
| KBV (P/B) | 3,23 vs. 4,07 (2021) ▼ |
|---|---|
| KUV (P/S) | 416,40 vs. 1.254,39 (2021) ▼ |
| FCF-Rendite | -12,0 % vs. -6,6 % (2021) ▼ |
Qualität & Bilanz
| Bruttomarge | 86,0 % |
|---|---|
| Operative Marge | -6.714,8 % vs. -9.990,9 % (2021) ▲ |
| Nettomarge | -6.046,2 % vs. -9.985,3 % (2021) ▲ |
| ROIC | -44,7 % vs. -32,0 % (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 4,07 | 3,12 | 4,50 | 3,59 | 4,48 | |
| KUV (P/S) | 1.254,39 | 208,14 | 604,45 | 4.572,96 | 578,09 | |
| FCF-Rendite | -6,6 % | -11,9 % | -7,1 % | -4,9 % | -8,6 % | |
| Qualität & Bilanz | ||||||
| Bruttomarge | – | – | 100,0 % | 100,0 % | 86,0 % | |
| Operative Marge | -9.990,9 % | -3.544,1 % | -5.547,2 % | -32.613,5 % | -6.714,8 % | |
| Nettomarge | -9.985,3 % | -3.460,4 % | -5.345,9 % | -28.720,7 % | -6.046,2 % | |
| ROIC | -32,0 % | -51,3 % | -36,3 % | -21,7 % | -44,7 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 10.734.000 | -127.845.000 | -1,23 | 1.401.323.000 | 1.280.646.000 |
| 2025-12-31 | 10-K | 7.696.000 | -465.317.000 | -4,95 | 1.126.257.000 | 992.083.000 |
| 2025-09-30 | 10-Q | 143.000 | -130.091.000 | -1,38 | 1.196.031.000 | 1.072.169.000 |
| 2025-06-30 | 10-Q | 1.031.000 | -115.637.000 | -1,23 | 1.289.574.000 | 1.171.526.000 |
| 2025-03-31 | 10-Q | 361.000 | -96.774.000 | -1,04 | 1.361.327.000 | 1.254.000.000 |
| 2024-12-31 | 10-K | 1.039.000 | -298.408.000 | -3,69 | 1.434.592.000 | 1.324.805.000 |
| 2024-09-30 | 10-Q | 0 | -76.828.000 | -0,96 | 937.374.000 | 832.980.000 |
| 2024-06-30 | 10-Q | 399.000 | -74.055.000 | -0,94 | 935.535.000 | 830.763.000 |
| 2024-03-31 | 10-Q | 640.000 | -66.930.000 | -0,93 | 978.153.000 | 874.933.000 |
| 2023-12-31 | 10-K | 4.013.000 | -214.529.000 | -3,69 | 635.353.000 | 539.106.000 |
| 2023-09-30 | 10-Q | 346.000 | -57.458.000 | -1,01 | 641.537.000 | 547.748.000 |
| 2023-06-30 | 10-Q | 988.000 | -50.979.000 | -0,94 | 293.254.000 | 254.116.000 |
| 2023-03-31 | 10-Q | 2.679.000 | -45.995.000 | -0,85 | 314.009.000 | 280.330.000 |
| 2022-12-31 | 10-K | 4.737.000 | -163.918.000 | -3,15 | 352.176.000 | 316.328.000 |
| 2022-09-30 | 10-Q | 458.000 | -41.925.000 | -0,78 | 384.880.000 | 351.372.000 |
| 2022-06-30 | 10-Q | 439.000 | -42.375.000 | -0,81 | 421.733.000 | 386.165.000 |
| 2022-03-31 | 10-Q | 3.131.000 | -34.627.000 | -0,73 | 333.286.000 | 303.044.000 |
| 2021-12-31 | 10-K | 1.078.000 | -107.641.000 | -2,80 | 351.015.000 | 331.944.000 |
| 2021-09-30 | 10-Q | 0 | -27.851.000 | -0,73 | 209.359.000 | 193.590.000 |
| 2021-06-30 | 10-Q | -26.095.000 | -0,70 | 216.929.000 | 201.440.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|
| Product | 5,4 Mio. | – | – | 70,4 % | Neu | |
| License And Service | 2,3 Mio. | 1,0 Mio. | 4,0 Mio. | 29,6 % | +119,1% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 07.05.2026 | 10,7 Mio. USD | -1,23 |
| Q3 2025 | 30.09.2025 | 06.11.2025 | 143.000 USD | -1,38 |
| Q2 2025 | 30.06.2025 | 07.08.2025 | 1,0 Mio. USD | -1,23 |
| Q1 2025 | 31.03.2025 | 07.05.2026 | 361.000 USD | -1,04 |
| Q3 2024 | 30.09.2024 | 06.11.2025 | 0 USD | -0,96 |
| Q2 2024 | 30.06.2024 | 07.08.2025 | 399.000 USD | -0,94 |
| Q1 2024 | 31.03.2024 | 08.05.2025 | 640.000 USD | -0,93 |
| Q3 2023 | 30.09.2023 | 12.11.2024 | 346.000 USD | -1,01 |
| Q2 2023 | 30.06.2023 | 08.08.2024 | 988.000 USD | -0,94 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 07.05.2026 | 10-Q | – | – | SEC » |
| 26.02.2026 | 10-K | 31.12.2025 | 57 Tage | SEC » |
| 06.11.2025 | 10-Q | 30.09.2025 | 37 Tage | SEC » |
| 07.08.2025 | 10-Q | 30.06.2025 | 38 Tage | SEC » |
| 08.05.2025 | 10-Q | 31.03.2025 | 38 Tage | SEC » |
| 27.02.2025 | 10-K | 31.12.2024 | 58 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 08.08.2024 | 10-Q | 30.06.2024 | 39 Tage | SEC » |
| 09.05.2024 | 10-Q | 31.03.2024 | 39 Tage | SEC » |
| 28.02.2024 | 10-K | 31.12.2023 | 59 Tage | SEC » |
| 07.11.2023 | 10-Q | 30.09.2023 | 38 Tage | SEC » |
| 08.08.2023 | 10-Q | 30.06.2023 | 39 Tage | SEC » |
| 09.05.2023 | 10-Q | 31.03.2023 | 39 Tage | SEC » |
| 28.02.2023 | 10-K | 31.12.2022 | 59 Tage | SEC » |
| 14.11.2022 | 10-Q | 30.09.2022 | 45 Tage | SEC » |
| 12.08.2022 | 10-Q | 30.06.2022 | 43 Tage | SEC » |
| 12.05.2022 | 10-Q | 31.03.2022 | 42 Tage | SEC » |
| 30.03.2022 | 10-K | 31.12.2021 | 89 Tage | SEC » |
| 05.11.2021 | 10-Q | 30.09.2021 | 36 Tage | SEC » |
| 10.08.2021 | 10-Q | 30.06.2021 | 41 Tage | SEC » |
| 06.05.2021 | 10-Q | 31.03.2021 | 36 Tage | SEC » |
| 30.03.2021 | 10-K | 31.12.2020 | 89 Tage | SEC » |
| 06.11.2020 | 10-Q | 30.09.2020 | 37 Tage | SEC » |
| 07.08.2020 | 10-Q | 30.06.2020 | 38 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 24.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which will… |
| 16.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 08.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 03.10.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 25.03.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.03.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 01.03.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 05.01.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.12.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 02.09.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 03.09.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |